TcLand Expression Launches a Multicenter Clinical Validation Study on Its K-RejX Diagnostic Blood Test
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
TcLand Expression SA has announced the launch of the KARE study (Kidney Allograft REjection).
This will be the international, multicentre, prospective clinical validation study for TcLand Expression’s K-RejX qPCR blood test, as a multi-gene molecular diagnostic tool to help in the identification of kidney transplant recipients at risk of chronic antibody-mediated rejection (CAMR). The KARE study will enroll 450 patients from over 30 European and North American large transplantation centers.
This will be the international, multicentre, prospective clinical validation study for TcLand Expression’s K-RejX qPCR blood test, as a multi-gene molecular diagnostic tool to help in the identification of kidney transplant recipients at risk of chronic antibody-mediated rejection (CAMR). The KARE study will enroll 450 patients from over 30 European and North American large transplantation centers.
